PDT Partners LLC Buys 312,794 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

PDT Partners LLC increased its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 2,111.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 327,608 shares of the company’s stock after buying an additional 312,794 shares during the period. PDT Partners LLC owned 0.32% of Intellia Therapeutics worth $3,820,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of NTLA. Barclays PLC raised its position in shares of Intellia Therapeutics by 17.7% in the 3rd quarter. Barclays PLC now owns 292,795 shares of the company’s stock worth $6,017,000 after acquiring an additional 44,022 shares in the last quarter. Virtu Financial LLC bought a new position in Intellia Therapeutics in the third quarter worth $417,000. Franklin Resources Inc. boosted its holdings in shares of Intellia Therapeutics by 10.3% during the 3rd quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock valued at $320,000 after buying an additional 1,538 shares in the last quarter. Green Alpha Advisors LLC purchased a new stake in Intellia Therapeutics in the fourth quarter worth about $138,000. Finally, AdvisorNet Financial Inc grew its stake in shares of Intellia Therapeutics by 96.4% in the 4th quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company’s stock worth $118,000 after buying an additional 4,950 shares during the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

NTLA has been the topic of a number of recent research reports. Barclays cut their target price on Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. BMO Capital Markets cut their price target on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a report on Friday, January 10th. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $9.00 price objective on shares of Intellia Therapeutics in a research report on Friday, February 28th. StockNews.com raised Intellia Therapeutics to a “sell” rating in a report on Monday, March 3rd. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $13.00 price target (down from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Two analysts have rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Intellia Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $36.68.

Intellia Therapeutics Trading Up 2.0 %

NASDAQ NTLA opened at $8.48 on Tuesday. The stock has a market cap of $877.82 million, a price-to-earnings ratio of -1.56 and a beta of 2.23. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $28.18. The company’s 50 day moving average is $8.59 and its two-hundred day moving average is $11.70.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.